0.8719

6.33% 0.0519

After Hours: .90 0.0281 +3.22%

Neurosense Therapeutics Ltd (NRSN)

Overview News Price History Discussions Forecast

Neurosense Therapeutics Ltd stock is traded at $0.8719, with a volume of 109.69K. It is up +6.33% in the last 24 hours and up +16.24% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Previous Close:

$0.82

Open:

$0.86

24h Volume:

109.69K

Relative Volume:

0.77

Market Cap:

$31.48M

Revenue:

Net Income/Loss:

$-10.21M

P/E Ratio:

-1.4925

EPS:

-0.5842

Net Cash Flow:

1W Performance:

+14.42%

1M Performance:

+16.24%

6M Performance:

-25.48%

1Y Performance:

-42.64%

1-Day Range:

$0.85

$0.8798

1-Week Range:

$0.7603

$0.8798

52-Week Range:

$0.63

$2.60

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name

Neurosense Therapeutics Ltd

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-06-30

Latest SEC Filings

NRSN's Discussions on Twitter

Compare NRSN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRSN Neurosense Therapeutics Ltd	0.8719	29.60M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Neurosense Therapeutics Ltd Stock (NRSN) Latest News

May 25, 2026

Amyotrophic Lateral Sclerosis (ALS) Market Set for Significant - openPR.com

May 25, 2026

May 21, 2026

NeuroSense Therapeutics (NRSN) Slides 4.56% as Support Levels Are TestedExpert Market Insights - Newser

May 21, 2026

May 15, 2026

TradingKey - TradingKey

May 15, 2026

May 11, 2026

NRSN (NeuroSense Therapeutics) Q2 loss narrows 6.9% more than expected, but investors await pipeline catalyst update.Expert Verified Trades - newser.com

May 11, 2026

Apr 29, 2026

NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price - The Globe and Mail

Apr 29, 2026

Apr 28, 2026

NeuroSense Announces Pricing of Insider-Led PIPE Financing - The Malaysian Reserve

Apr 28, 2026

NeuroSense (Nasdaq: NRSN) insiders lead $600K PIPE financing at premium - Stock Titan

Apr 28, 2026

Apr 27, 2026

NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding - marketscreener.com

Apr 27, 2026

Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo

Apr 27, 2026

Apr 25, 2026

NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail

Apr 25, 2026

Apr 24, 2026

NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan

Apr 24, 2026

Apr 18, 2026

Tangible book value per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Apr 17, 2026

EBIT per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Apr 17, 2026

Operating cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView

Apr 17, 2026